Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD3 long-term extension study of ESK-001 in adults with moderate to severe plaque psoriasis
MOH_2025-03-25_013988Phase 3Not yet recruiting
- Sponsor
- Alumis Inc.
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of envudeucitinib in plaque psoriasis (3 arms), sponsored by Alumis Inc. Primary endpoints: Long-term safety and tolerability of ESK-001 and Long-term efficacy of ESK-001. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on MOH_2025-03-25_013988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-25_013988.